Faruqi & Faruqi, LLP is investigating the claims on behalf of investor Kyverna Therapeutics By Investing.com

admin2 days ago

0 0 2 minutes read

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson encourages investors who have suffered losses greater than $50,000 in Kyverna to contact him directly to discuss their options

If you have incurred losses in excess of $50,000 by investing in Kyverna common stock pursuant to and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about February 8, 2024 (the “IPO” or “Offer”) and want to discuss your legal rights, call a Faruqi & Faruqi partner Josh Wilson direct on 877-247-4292 or 212-983-9330 (ext. 1310).

[You may also click here for additional information]

New York, New York–(Newsfile Corp. – January 4, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kyverna Therapeutics, Inc . (“Kyverna” or the “Company”) (NASDAQ: KYTX) and reminds investors of The deadline is February 7, 2025 to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The company has recovered hundreds of millions of dollars for investors since its inception in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws through the registration statement and prospectus used to effectuate the Company’s IPO, misrepresented and/or omitted facts regarding to the results of the Company’s ongoing evaluation of KYV-101 in clinical trials. Specifically, the Company touted patient “improvement” in certain metrics, and did not disclose negative data related to one of Kyverna’s trials, which negative data was known to the Company at the time of the IPO. As a result, investors bought Kyverna shares at artificially inflated prices.

As these true facts emerged after the Offer, the Company’s shares fell sharply, seriously harming investors. Prior to this action, Kyverna’s stock was trading at just $3.92 per share, a drop of more than 82% from the offer price.

A court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who is adequate and typical of the class members and who directs and oversees the litigation on behalf of the putative class. Any putative class member may propose to the Court to serve as lead plaintiff through counsel of his or her choosing, or may choose to do nothing and remain an absent class member. Your ability to participate in any recovery is not affected by the decision whether or not you will be the lead plaintiff.

Faruqi & Faruqi, LLP also encourages anyone with information about Kyverna’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

Advertising of lawyers. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your specific case. All communications will be treated confidentially.

To view the original version of this press release, visit https://www.newsfilecorp.com/release/236024

Source link